Stryker SYK MedSurg and Neurotechnology: — Reclassification to: cost of sales

Other segment segments

Similar metrics at other companies

SOLVMedSurg — Cost of Sales

$595M-1.3%

CHDConsolidating Reclassification — Cost Of Revenue

$17.9M+9.1%

HAEMedSurg — Cost of goods sold

$50.37M+0.3%

CFAN — Cost of Sales

$75M-18.5%

CCSLand Sales And Other — Cost Of Revenue

$1.68M+2,332%

LZBRetail — Cost of Sales

$116.98M+7.6%

FAQ

What is Stryker's medsurg and neurotechnology: — reclassification to: cost of sales?

Stryker (SYK) reported medsurg and neurotechnology: — reclassification to: cost of sales of $1.29B in Q1 2026.

How has Stryker's medsurg and neurotechnology: — reclassification to: cost of sales changed year-over-year?

Stryker's medsurg and neurotechnology: — reclassification to: cost of sales increased by 9.9% year-over-year, from $1.18B to $1.29B.

What is the long-term trend for Stryker's medsurg and neurotechnology: — reclassification to: cost of sales?

Over 3 years (2022 to 2025), Stryker's medsurg and neurotechnology: — reclassification to: cost of sales has grown at a 7.2% compound annual growth rate (CAGR), from $4.64B to $5.71B.

What does medsurg and neurotechnology: — reclassification to: cost of sales mean?

Captures specific expenses or costs previously categorized elsewhere that have been reallocated to the cost of sales for the MedSurg and Neurotechnology segment. This adjustment ensures that the direct costs of manufacturing and delivering products are accurately reflected in the gross margin calculation. It provides transparency into the true cost structure of the segment's revenue generation.